ILAPRAZOLE

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C19H18N4O2S
Molecular Weight	366.4386
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cc1c(CS(=O)c2nc3ccc(cc3[nH]2)-n4cccc4)nccc1OC

InChI

InChIKey=HRRXCXABAPSOCP-UHFFFAOYSA-N

InChI=1S/C19H18N4O2S/c1-13-17(20-8-7-18(13)25-2)12-26(24)19-21-15-6-5-14(11-16(15)22-19)23-9-3-4-10-23/h3-11H,12H2,1-2H3,(H,21,22)

HIDE SMILES / InChI

Molecular Formula	C19H18N4O2S
Molecular Weight	366.4386
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11304936 | https://www.ncbi.nlm.nih.gov/pubmed/11215326 | http://www.drugsupdate.com/generic/view/1243 | http://eng.dailypharm.com/News/news_view.html?ID=362 | https://www.ncbi.nlm.nih.gov/pubmed/28388576 | http://www.pharmalink.kr/detailinfo.php?code=20081068801

Ilaprazole or IY-81149 (2-[(4-methoxy-3-methyl)-2-pyridinyl]methylsulfinyl -5-(1H-pyrrol-1-yl)-1H-benzimidazole, CAS 172152-36-2) is a proton pump inhibitor. Ilaprazole revealed the characteristics as a strong proton pump inhibitor, and its potency against gastric acid secretion was superior to that of the reference drug, omeprazole. Ilaprazole is approved in China and South Korea for the treatment of gastroesophageal reflux disorders (GERD), dyspepsia and peptic ulcers. Recently it was discovered that ilaprazole inhibited the cancer growth by targeting T-cell-originated protein kinase (TOPK) both in vitro and in vivo.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sodium/potassium-transporting ATPase 32 Target ID: CHEMBL2095186 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11304936	Inhibitor 7701	Gastroesophageal reflux disease Peptic ulcer	6 µM [IC50]
PDZ-binding kinase 1 Target ID: CHEMBL4896 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28388576	Inhibitor 7701	Colon cancer	111 µM [Kd]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Colon cancer 61 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28388576	Primary	PDZ-binding kinase	Preclinical
Gastroesophageal reflux disease 56 Sources: http://adisinsight.springer.com/drugs/800010706	Primary	Sodium/potassium-transporting ATPase	Approved 7997	Noltec Approved Use Ilaprazole is used for the treatment of gastroesophageal reflux disorders (GERD), dyspepsia and peptic ulcers. Launch Date 1191110400000
Peptic ulcer 70 Sources: http://adisinsight.springer.com/drugs/800010706	Primary	Sodium/potassium-transporting ATPase	Approved 7997	Noltec Approved Use Ilaprazole is used for the treatment of gastroesophageal reflux disorders (GERD), dyspepsia and peptic ulcers. Launch Date 1191110400000

PubMed

Title	Date	PubMed
Comparison of IY81149 with omeprazole in rat reflux oesophagitis.	2000 Oct-Dec	11350494

Patents

Sample Use Guides

In Vivo Use Guide

Short-term treatment of duodenal ulcer: Normally, 10 mg of adult is administered orally once a day. It is usually administered for up to 4 weeks.

Route of Administration: Oral

In Vitro Use Guide

Ilaprazole exhibited potent inhibitory activities against the growth of HCT116 cells (IC50 = 40 uM) and ES-2 cells (IC50 = 33.2 uM). Ilaprazole (100 and 50 uM) induces apoptosis in ES-2 and HCT116 cells.

Substance Class	Chemical Created by `admin` on `Sat Jun 26 11:40:35 UTC 2021` Edited by `admin` on `Sat Jun 26 11:40:35 UTC 2021`
Record UNII	776Q6XX45J
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ILAPRAZOLE

Official Name

English

NOLTEC

Brand Name

English

IY-81149

Systematic Name

English

ILAPRAZOLE [INN]

Common Name

English

ILAPRAZOLE [WHO-DD]

Common Name

English

2-((RS)-((4-METHOXY-3-METHYLPYRIDIN-2-YL)METHYL)SULFINYL)-5-(1H-PYRROL-1-YL)-1H-BENZIMIDAZOLE

Systematic Name

English

ILAPRAZOLE [MART.]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29723